cobas CMV Test
by Roche Molecular Systems, Inc.
PMA P160041510(k) K252481
Active
Valid until
No expiry
FDA recalls
None found
Documents
Trust
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE 510(k) | NumberK252481 | Date3 Nov 2025 | StatusActive |
| United States | FDA PMA PMA | NumberP160041 | Date1 Jun 2017 | StatusActive |
Official records
- FDA 510(k) database K252481
- FDA PMA database P160041
From the FDA record
FDA PMA P160041
- Received by the FDA
- 7 Aug 2025
- FDA decision
- 3 Nov 2025 (Substantially Equivalent)
- FDA review time
- 88 days from receipt to decision
- Docket number
- 17M-3430
Approval of the cobas CMV test - This device is indicated for:cobas® CMV is an in vitro nucleic acid amplification test for the quantitation of cytomegalovirus (CMV) DNA in human EDTA plasma. cobas® CMV is intended for use as an aid in the management of CMV in solid organ transplant patients and in hematopoietic stem cell transplant patients. In patients receiving anti-CMV therapy, serial DNA measurements can be used to assess viral response to treatment. The results from cobas® CMV must be interpreted within the context of all relevant clinical and laboratory findings. cobas® CMV is not intended for use as a screening test for blood or blood products.
Across registries
- FDA 510(k) K252481 decided 3 Nov 2025 Active
- FDA PMA P160041 decided 1 Jun 2017 Active
Timeline
- Approved FDA PMA P160041
- Cleared FDA 510(k) K252481
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k), FDA PMA Active
Specification
- Trade name
- Cobas Cmv
- Generic name
- Cytomegalovirus (cmv) dna quantitative assay
- PMA number
- 510(k) Number
- FDA product code
- PAB
- Device class
- Class II
- Regulation
- 21 CFR Part 866.3180
- Advisory committee
- Microbiology
- FDA decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 18 Sep 2026
The cobas CMV Test is an in vitro nucleic acid amplification assay for the quantitative detection of cytomegalovirus (CMV) DNA in human EDTA plasma. Classified as a microbiology device under the FDA’s nomenclature, it provides measurable viral load results to aid in clinical decision-making for CMV management.
This test is intended for use in solid organ and hematopoietic stem cell transplant patients to monitor CMV infection and assess response to anti-CMV therapy. Supplied as a single-use reagent kit, it requires laboratory processing and is not approved for blood screening. Authorized under FDA 510(k) clearance (K252481) and PMA (P160041), compliance with regulatory standards ensures accurate quantitation of CMV DNA for clinical management.
Similar devices
Other devices filed under FDA product code PAB (Cytomegalovirus (Cmv) Dna Quantitative Assay).